Oxford Events, the new replacement for OxTalks, will launch on 16th March. The two-week OxTalks freeze period starts on Monday 2nd March. During this time, there will be no facility to publish or edit events. The existing OxTalks site will remain available to view during this period. Once Oxford Events launches, you will need a Halo login to submit events. Full details are available on the Staff Gateway.
Claire is currently a Partner in the Life Science team at Oxford Science Enterprises, an investment company that creates transformational businesses via a unique partnership with the University of Oxford, UK, the world’s #1 research university. Her focus is building and investing in novel therapeutics and therapeutic platforms across diverse therapy areas and modalities. She currently supports a number of OSE’s emerging companies incl. T-Cypher Bio, Nucleome, Alveogene and Orfonyx. Claire has spent the majority of her career in the global BioPharmaceutical industry at UCB Group, Sanofi-Genzyme and AstraZeneca where she worked in a variety of roles covering R&D strategy, licensing and corporate VC.
